Stryker (SYK) Q4 FY25 earnings call

Stryker delivered robust Q4 FY25 results, driven by double-digit organic sales growth across most divisions and record Mako installations. The company achieved significant adjusted operating margin expansion despite tariff headwinds and generated strong cash flow. Management expresses confidence in continued high-end med tech growth for FY26, supported by a healthy capital order book and ongoing product innovation.